Post-Market Clinical Study of the PanOptix Intraocular Lens (IOL) in a Chinese Population

NACompletedINTERVENTIONAL
Enrollment

181

Participants

Timeline

Start Date

April 19, 2021

Primary Completion Date

August 31, 2022

Study Completion Date

March 15, 2023

Conditions
AphakiaPresbyopia
Interventions
DEVICE

AcrySof IQ PanOptix Presbyopia Correcting IOL

UV and blue-light filtering foldable multifocal IOL with a +2.17 diopter (D) addition power of intermediate visual acuity and a +3.25 D addition power of near visual acuity. This device is approved in China.

PROCEDURE

Cataract surgery

Cataract extraction by phacoemulsification, followed by implantation of the AcrySof IQ PanOptix Presbyopia Correcting IOL

Trial Locations (9)

100044

Peking University People's Hospital, Beijing

100730

Beijing Tongren Hospital Capital Medical University, Beijing

200031

Eye & ENT Hospital of Fudan University, Shanghai

250002

Ophthalmic Hospital Affiliated to Shandong University of Traditional Chinese Medicine, Shandong

300384

Tianjin Medical University Eye Hospital, Tianjin

310009

The Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou

510060

Zhongshan Ophthalmic Center, Sun Yat-Sen University, Guandong

610041

West China Hospital of Sichuan University, Sichuan

710068

Shanxi Eye Hospital, Shanxi

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Alcon Research

INDUSTRY

NCT04755231 - Post-Market Clinical Study of the PanOptix Intraocular Lens (IOL) in a Chinese Population | Biotech Hunter | Biotech Hunter